Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | POLQ | O75417 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590637 | 0.91 | P2RX7 (0.44) | P2RX7POLBANO1AKR1B1TRPV1 | |
| SCHEMBL1591666 | 0.87 | P2RX7 (0.51) | P2RX7POLBTRPV1KCNQ2NTRK1 | |
| SCHEMBL1590578 | 0.85 | P2RX7 (0.49) | P2RX7AKR1B1NTRK1 | |
| SCHEMBL1590205 | 0.83 | P2RX7 (0.68) | P2RX7POLBPOLQKCNH2AKR1B1 | |
| SCHEMBL1590501 | 0.83 | P2RX7 (0.70) | P2RX7POLBPOLQTRPV1NTRK1 | |
| SCHEMBL1591890 | 0.83 | P2RX7 (0.61) | P2RX7TRPV1KCNQ2NTRK1 | |
| SCHEMBL1590252 | 0.83 | P2RX7 (0.56) | P2RX7KCNQ2NTRK1 | |
| SCHEMBL1591202 | 0.82 | P2RX7 (0.57) | P2RX7POLBPOLQKCNH2AKR1B1 | |
| SCHEMBL1590200 | 0.82 | P2RX7 (0.72) | P2RX7POLBTRPV1KCNQ2 | |
| SCHEMBL13587570 | 0.81 | P2RX7 (0.58) | P2RX7POLBPOLQKCNH2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2011-04-21 | — | — | US | claimed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | claimed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | claimed |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2011-04-21 | — | — | US | disclosed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885POLB 3676/4885POLQ 4130/4885 |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885POLB 3676/4885POLQ 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.